Fusion Antibodies PLC
FAB
Company Profile
Business description
Fusion Antibodies PLC is in the research, development and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It has single segment of research, development and manufacture of recombinant proteins and antibodies. It has presence in UK, Rest of Europe, and North America and Rest of World.
Contact
1 Springbank Road
Springbank Industrial Estate
Dunmurry
BelfastBT17 0QL
GBRT: +44 2890432800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
27
Stocks News & Analysis
stocks
CBA earnings: Business lending powers on, but costs and credit bear watching
Our view after the bank reports first quarter earnings.
stocks
Apple earnings review: Revenue beats estimates as memory crunch threatens margins
Apple shares are trading at record highs after posting solid results.
stocks
Nvidia: Cutting our fair value estimate by 19% given the firm’s CEO transition and turmoil
We’re reducing our long-term revenue estimates.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,204.50 | 69.70 | -0.75% |
| CAC 40 | 8,368.91 | 7.55 | 0.09% |
| DAX 40 | 26,749.95 | 21.93 | -0.08% |
| Dow JONES (US) | 52,309.66 | 12.57 | 0.02% |
| FTSE 100 | 10,902.56 | 39.47 | 0.36% |
| HKSE | 23,637.60 | 370.95 | -1.55% |
| NASDAQ | 25,130.66 | 235.43 | -0.93% |
| Nikkei 225 | 61,142.35 | 322.99 | 0.53% |
| NZX 50 Index | 14,173.68 | 85.55 | -0.60% |
| S&P 500 | 7,554.71 | 37.69 | -0.50% |
| S&P/ASX 200 | 9,082.20 | 64.60 | -0.71% |
| SSE Composite Index | 3,634.35 | 21.48 | -0.59% |